Dyadic International, Inc. announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc. Under the agreement, Dyadic and Fermbox expect to use Dyadic's proprietary Dapibus filamentous fungal based microbial protein production platform and Fermbox's extensive product development capabilities, to design, develop and commercialize innovative animal free alternative proteins and biomaterials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 USD | 0.00% | -6.29% | -7.45% |
Mar. 28 | Transcript : Dyadic International, Inc., 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Dyadic International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.45% | 43.56M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- DYAI Stock
- News Dyadic International, Inc.
- Dyadic International, Inc. Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™